Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 7/20/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Mark Gelder?

Mark S. Gelder

Senior Vice President and Chief Medical Officer

Heron Therapeutics Inc

HQ Phone:  (650) 366-2626

Email: m***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Heron Therapeutics Inc

123 Saginaw Drive 123 Saginaw Drive

Redwood City, California,94063

United States

Company Description

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing novel best-in-class treatments that address some of the biggest unmet patient needs. Heron is developing novel, patient-focused soluti...more

Background Information

Employment History

Senior Vice President and Chief Medical Officer

A.P. Pharma Inc


Vice President Clinical Development

Inovio Pharmaceuticals , Inc.


Vice President, Global Medical Affairs, Oncology

Bayer AG


Vice President, Global Head Medical Affairs and PV, Medical Diagnostics and NPD

GE Healthcare Ltd


Global Therapeutic Area Director of Oncology

Wyeth


Vice President Global Medical Affairs and Oncology

Bayer HealthCare AG


Web References(27 Total References)


Heron Therapeutics • A Biotechnology Company

www.herontx.com [cached]

Mark Gelder, M.D.
Senior VP, Chief Medical Officer Mark Gelder, M.D. Senior VP, Chief Medical Officer Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. From October 2007 to December 2011, Dr. Gelder was the Vice President and Global Head of Medical Affairs and Pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure at GE Healthcare, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the Vice President of Global Medical Affairs of Oncology for Bayer HealthCare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar® (sorafanib), Stivarga® (regorafenib), and Alpharadin® (now called Xofigo )(radium 223 dichloride) global programs. Dr. Gelder was also the Global Therapeutic Area Director of Oncology at Wyeth from December 2005 to October 2007, with a focus on the commercial launch of Torisel® (temsirolimus). Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, Inc., working on Sutent® (sunitinib malate), and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received his B.S. degree in biochemistry from Colgate University, and his M.D. degree from the University of Virginia's School of Medicine.


phx.corporate-ir.net

Mark S. Gelder


Heron Therapeutics . A Biotechnology Company • Investor Relations • News Release

phx.corporate-ir.net [cached]

A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer Mark S. Gelder , M.D. as senior vice president and chief medical officer. The addition of Dr. Gelder to A.P. Pharma’s executive team represents the Company’s continued efforts related to pre-commercialization activities for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved. Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare , Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals , and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga®, and Alpharadin® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth , with a focus on the commercial launch of Torisel®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor’s of science degree from


Heron Therapeutics • Management

www.appharma.com [cached]

Mark S. Gelder, M.D.
Senior VP, Chief Medical Officer Mark S. Gelder, M.D. Senior VP, Chief Medical Officer Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga®, and Alpharadin® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth, with a focus on the commercial launch of Torisel®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor's of science degree from Colgate University, and his doctor of medicine from the University of Virginia's School of Medicine.


ir.inovio.com

Mark Stephen Gelder
, M.D., an experienced gynecologic oncologist, was appointed Vice President, Clinical Development to lead Inovio's clinical development of its immunotherapies against HPV-caused cervical cancer and dysplasia, including our planned phase III study for VGX-3100. Prior to joining Inovio he was Chief Medical Officer at


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory